Biovail was a large international pharmaceutical company with reported revenues of $788 million. Banc of America has issued a research report which indicates that Biovail Corporation's financial statements raised a number of issues that warrant caution for investors, and as a result, Biovail's stock was given a sell rating by Banc of America. A member of Biovail's audit committee is preparing for an upcoming audit meeting and considers .....more

Elite Inc. is a highly successful public relations firm. Elite's chief financial officer has been spending 18-hour days in an effort to get his work done. The newly appointed chief executive officer must determine the cause of the excessive workload and develop a strategy to deal with the chief financial officer's performance. The supplement Elite Inc. (B), product 9B03C040 discusses the implementation of the strategy and its outcome.

In this supplement to Elite Inc. (A), product 9B03C039, the chief executive officer has prepared and implemented a strategy to resolve the below standard performance of the chief financial officer. At the company's mid-term audit meeting, the chief financial officer had once again performed poorly, causing embarrassment and the humiliation for the chief executive officer. The chief executive officer must make a decision about the chief financial .....more

Biovail was a large international pharmaceutical company with reported revenues of $788 million. Banc of America has issued a research report which indicates that Biovail Corporation's financial statements raised a number of issues that warrant caution for investors, and as a result, Biovail's stock was given a sell rating by Banc of America. A member of Biovail's audit committee is preparing for an upcoming audit meeting and considers .....more

Teaching note for product 9B04B011.

Teaching note for products 9B04N007 and 9B04N008.

Biovail Corporation, a large pharmaceutical company, recently had its stock downgraded by a well known pharmaceutical analyst and a number of other analysts were also scrutinizing the company. The outcome was not favorable, as Biovail's acquisition methods were labeled as unethical and their accounting practices were questioned. An investor with the company must decide if she will continue to invest in a company that has been identified with low .....more

In this supplement to Biovail Corporation (A), product 9B04N007, an investor in Biovail made the decision to sell her stock in the company based on published reports from a well known pharmaceutical analyst. She later finds out that this analyst had an interest in Biovail's competition and wonders if she should reconsider her decision.

In this supplement to Elite Inc. (A), product 9B03C039, the chief executive officer has prepared and implemented a strategy to resolve the below standard performance of the chief financial officer. At the company's mid-term audit meeting, the chief financial officer had once again performed poorly, causing embarrassment and the humiliation for the chief executive officer. The chief executive officer must make a decision about the chief financial .....more

Teaching note for product 9B03C028.